期刊文献+

肾功能不全患者芬太尼族药物的药动学 被引量:1

The Pharmacokinetics of Fentanyl Family Drugs in Patients with Renal Inadequacy
暂未订购
导出
摘要 芬太尼族药物包括芬太尼、瑞芬太尼、舒芬太尼和阿芬太尼等,已广泛用于临床麻醉及术后镇痛。肾功能不全患者常伴有贫血、低血容量和低蛋白血症,许多药物不良反应发生率明显高于肾功能正常者。肾功能不全时芬太尼族药物的吸收、分布、生物转化和排泄等都可能发生改变。总结分析对肾功能不全患者芬太尼族药物药动学研究的进展,有助于指导临床用药,减少药物不良反应。 Fentanyl, rerifentanil, sufentauil, and alfe^anil are the fentanyl family" of drugs. They have been widely used in clinical anesthesia and postoperative analgesia. Patients with renal inadequacy often have anemia,hypovolemia and hypoproteinemia, the incidence of adverse drug reactions in patients with renal inadequacy is significantly higher than in patients with the normal renal function. The absorption, distribu- tion,biotransformation and excretion of fentanyl family of drugs may change in patients with renal failure. Here is to make a review of pharmacokinetics of the fentanyl family of drugs in patients with renal failure and provide guidance for clinical medication, reducing adverse drug reactions.
出处 《医学综述》 2013年第11期2045-2047,共3页 Medical Recapitulate
关键词 肾功能不全 芬太尼 舒芬太尼 瑞芬太尼 阿芬太尼 药动学 Renal insufficiency Fentanyl Sufentail Remifentanil Alfentanil Pharmacokinetics
  • 相关文献

参考文献7

二级参考文献72

共引文献61

同被引文献20

  • 1Greaves SC,Gamble GD,Collins JF,et al.Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure[J].Am J Kidney Dis,1994,24(5):768-776.
  • 2Washio M,Okuda S,Mizoue T,et al.Risk factors for left ventricular hypertrophy in chronic hemodialysis patients[J].Clin Nephrol,1997,47(6):362-366.
  • 3Ronald MA,Henry RM,Pite Y,et al.Mild renal insufficiency is associated with increased cardiovascular mortality:the hoorn study[J].Kidney Int,2002,62(4):1402-1407.
  • 4Eschbach JW.Current concepts of anemia management in chronic renal failure:impact of NKF-DOQI[J].Semin Nephrol,2010,20(4):320-329.
  • 5Locatelli F,Pisoni RL,Combe C,et al.Anaemia in haemodialysis patients of five european countries:association with morbidity and mortality in the dialysis outcomes and practice patterns study(DOPPS)[J].Nephrol Dial Transplant,2011,19(1):121-132.
  • 6Portolés J,López Gómez JM,Aljama PA.Prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients:the mar study[J].Nephrol Dial Transplant,2007,22(2):500-507.
  • 7Gilbertson DT,Ebben JP,Foley RN,et al.Hemoglobin level variability:associations with mortality[J].Clin J Am Soc Nephrol,2008,3(1):133-138.
  • 8Plantinga LC,Fink NE,Jaar BG,et al.Relation between level or change of hemoglobin and generic and disease-specific quality of life in h dialysis[J].Qual Life Res,2007,16(5):755-765.
  • 9Frank H,Heusser K,Hffken B,et al.Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients[J].Kidney Int,2011,66(2):832-840.
  • 10Thanakitcharu P,Siriwiwatanakul N.Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia[J].J Med Assoc Thai,2007,90(12):2574-2586.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部